Which has higher valuation & earnings, ZTS or SNY?

Sanofi has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zoetis $9.53B 3.17 $2.67B $6.07 12.03 Sanofi $48.92B 2.12 $8.84B $1.91 22.39

Is ZTS or SNY more profitable?

Zoetis has a net margin of 27.49% compared to Sanofi's net margin of 8.66%. Zoetis' return on equity of 74.89% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Zoetis 27.49% 74.89% 18.59% Sanofi 8.66% 14.19% 7.95%

Does the media favor ZTS or SNY?

In the previous week, Zoetis had 15 more articles in the media than Sanofi. MarketBeat recorded 19 mentions for Zoetis and 4 mentions for Sanofi. Zoetis' average media sentiment score of 1.34 beat Sanofi's score of 1.21 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 15 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ZTS or GSK?

GSK has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zoetis $9.53B 3.17 $2.67B $6.07 12.03 GSK $43.07B 2.26 $7.54B $3.20 15.04

Is ZTS or GSK more profitable?

Zoetis has a net margin of 27.49% compared to GSK's net margin of 14.56%. Zoetis' return on equity of 74.89% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets Zoetis 27.49% 74.89% 18.59% GSK 14.56% 43.23% 11.60%

Does the media refer more to ZTS or GSK?

In the previous week, Zoetis had 5 more articles in the media than GSK. MarketBeat recorded 19 mentions for Zoetis and 14 mentions for GSK. Zoetis' average media sentiment score of 1.34 beat GSK's score of 0.39 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 15 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TAK or ZTS?

Zoetis has a consensus price target of $101.08, indicating a potential upside of 38.36%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Zoetis 2 Sell rating(s) 9 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.32

Does the media favor TAK or ZTS?

In the previous week, Zoetis had 18 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 19 mentions for Zoetis and 1 mentions for Takeda Pharmaceutical. Zoetis' average media sentiment score of 1.34 beat Takeda Pharmaceutical's score of 0.56 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 15 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TEVA or ZTS?

In the previous week, Zoetis had 1 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 19 mentions for Zoetis and 18 mentions for Teva Pharmaceutical Industries. Zoetis' average media sentiment score of 1.34 beat Teva Pharmaceutical Industries' score of 0.73 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 15 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ONC or ZTS?

Zoetis has higher revenue and earnings than BeOne Medicines. Zoetis is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $6.13B 6.21 $286.93M $5.68 61.01 Zoetis $9.53B 3.17 $2.67B $6.07 12.03

Is ONC or ZTS more profitable?

Zoetis has a net margin of 27.49% compared to BeOne Medicines' net margin of 10.70%. Zoetis' return on equity of 74.89% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 10.70% 14.23% 7.82% Zoetis 27.49% 74.89% 18.59%

Does the media favor ONC or ZTS?

In the previous week, Zoetis had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 19 mentions for Zoetis and 10 mentions for BeOne Medicines. Zoetis' average media sentiment score of 1.34 beat BeOne Medicines' score of 1.28 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 15 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zoetis (ZTS) Competitors

$73.05 +0.19 (+0.26%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$73.20 +0.15 (+0.20%)

As of 09/11/2026 08:00 PM Eastern

Compare

ZTS vs. SNY, GSK, TAK, TEVA, and ONC

Should you buy Zoetis stock or one of its competitors? Zoetis's main competitors and comparable companies include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zoetis compare to Sanofi?

Zoetis (NYSE:ZTS) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

92.8% of Zoetis shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sanofi has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.53B	3.17	$2.67B	$6.07	12.03
Sanofi	$48.92B	2.12	$8.84B	$1.91	22.39

In the previous week, Zoetis had 15 more articles in the media than Sanofi. MarketBeat recorded 19 mentions for Zoetis and 4 mentions for Sanofi. Zoetis' average media sentiment score of 1.34 beat Sanofi's score of 1.21 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	15 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.9%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Zoetis pays out 34.9% of its earnings in the form of a dividend. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis has raised its dividend for 14 consecutive years.

Zoetis has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Zoetis currently has a consensus price target of $101.08, suggesting a potential upside of 38.36%. Sanofi has a consensus price target of $49.50, suggesting a potential upside of 15.74%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Sanofi	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.38

Zoetis has a net margin of 27.49% compared to Sanofi's net margin of 8.66%. Zoetis' return on equity of 74.89% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
Sanofi	8.66%	14.19%	7.95%

Summary

Zoetis beats Sanofi on 13 of the 20 factors compared between the two stocks.

How does Zoetis compare to GSK?

Zoetis (NYSE:ZTS) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

GSK has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.53B	3.17	$2.67B	$6.07	12.03
GSK	$43.07B	2.26	$7.54B	$3.20	15.04

Zoetis has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, Zoetis had 5 more articles in the media than GSK. MarketBeat recorded 19 mentions for Zoetis and 14 mentions for GSK. Zoetis' average media sentiment score of 1.34 beat GSK's score of 0.39 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	15 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zoetis presently has a consensus target price of $101.08, suggesting a potential upside of 38.36%. GSK has a consensus target price of $53.00, suggesting a potential upside of 10.11%. Given Zoetis' stronger consensus rating and higher possible upside, equities analysts clearly believe Zoetis is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
GSK	2 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.9%. GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.7%. Zoetis pays out 34.9% of its earnings in the form of a dividend. GSK pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 14 consecutive years.

Zoetis has a net margin of 27.49% compared to GSK's net margin of 14.56%. Zoetis' return on equity of 74.89% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
GSK	14.56%	43.23%	11.60%

Summary

Zoetis beats GSK on 14 of the 20 factors compared between the two stocks.

How does Zoetis compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Zoetis has a net margin of 27.49% compared to Takeda Pharmaceutical's net margin of 3.80%. Zoetis' return on equity of 74.89% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Zoetis	27.49%	74.89%	18.59%

Takeda Pharmaceutical has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Zoetis had 18 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 19 mentions for Zoetis and 1 mentions for Takeda Pharmaceutical. Zoetis' average media sentiment score of 1.34 beat Takeda Pharmaceutical's score of 0.56 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	15 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has lower revenue, but higher earnings than Takeda Pharmaceutical. Zoetis is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.62T	0.01	-$1.01B	$0.34	53.72
Zoetis	$9.53B	3.17	$2.67B	$6.07	12.03

Zoetis has a consensus price target of $101.08, indicating a potential upside of 38.36%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.9%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis pays out 34.9% of its earnings in the form of a dividend. Zoetis has increased its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Zoetis beats Takeda Pharmaceutical on 16 of the 20 factors compared between the two stocks.

How does Zoetis compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Zoetis has a net margin of 27.49% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Zoetis' return on equity of 74.89% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Zoetis	27.49%	74.89%	18.59%

Teva Pharmaceutical Industries currently has a consensus price target of $43.10, suggesting a potential upside of 16.46%. Zoetis has a consensus price target of $101.08, suggesting a potential upside of 38.36%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

Teva Pharmaceutical Industries has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

Zoetis has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Zoetis is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.50	$1.41B	$0.60	61.68
Zoetis	$9.53B	3.17	$2.67B	$6.07	12.03

In the previous week, Zoetis had 1 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 19 mentions for Zoetis and 18 mentions for Teva Pharmaceutical Industries. Zoetis' average media sentiment score of 1.34 beat Teva Pharmaceutical Industries' score of 0.73 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	6 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	15 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zoetis beats Teva Pharmaceutical Industries on 10 of the 16 factors compared between the two stocks.

How does Zoetis compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Zoetis has a net margin of 27.49% compared to BeOne Medicines' net margin of 10.70%. Zoetis' return on equity of 74.89% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Zoetis	27.49%	74.89%	18.59%

BeOne Medicines presently has a consensus price target of $402.71, indicating a potential upside of 16.22%. Zoetis has a consensus price target of $101.08, indicating a potential upside of 38.36%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

In the previous week, Zoetis had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 19 mentions for Zoetis and 10 mentions for BeOne Medicines. Zoetis' average media sentiment score of 1.34 beat BeOne Medicines' score of 1.28 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	15 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Zoetis has higher revenue and earnings than BeOne Medicines. Zoetis is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$6.13B	6.21	$286.93M	$5.68	61.01
Zoetis	$9.53B	3.17	$2.67B	$6.07	12.03

BeOne Medicines has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Summary

Zoetis beats BeOne Medicines on 11 of the 17 factors compared between the two stocks.

Get Zoetis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZTS vs. The Competition

Export

Metric	Zoetis	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$30.11B	$12.43B	$7.16B	$23.20B
Dividend Yield	2.89%	2.62%	2.56%	3.56%
P/E Ratio	12.03	797.20	272.98	28.69
Price / Sales	3.17	758.78	654.99	102.56
Price / Cash	9.63	89.25	77.04	33.82
Price / Book	9.66	10.39	10.33	4.74
Net Income	$2.67B	$2.83B	$3.49B	$1.07B
7 Day Performance	-3.50%	-3.66%	-3.33%	-1.99%
1 Month Performance	-0.57%	0.82%	-0.42%	-2.68%
1 Year Performance	-50.75%	3.50%	19.22%	10.45%

Zoetis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZTS Zoetis	4.7276 of 5 stars	$73.05 +0.3%	$101.08 +38.4%	-51.5%	$30.11B	$9.53B	12.03	14,500	Positive News Analyst Forecast
SNY Sanofi	3.5588 of 5 stars	$44.24 flat	$49.50 +11.9%	-10.2%	$107.26B	$49.35B	23.16	74,846	News Coverage Analyst Forecast
GSK GSK	4.0616 of 5 stars	$49.88 0.0%	$53.00 +6.3%	+16.1%	$100.89B	$43.07B	15.60	66,841	News Coverage Dividend Cut Analyst Forecast
TAK Takeda Pharmaceutical	1.5938 of 5 stars	$18.46 +0.1%	N/A	+19.0%	$59.15B	$28.32B	54.29	47,000
TEVA Teva Pharmaceutical Industries	3.9247 of 5 stars	$36.36 flat	$42.89 +18.0%	+86.1%	$42.37B	$17.26B	60.60	33,950	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZTS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zoetis (ZTS) Competitors

ZTS vs. SNY, GSK, TAK, TEVA, and ONC

How does Zoetis compare to Sanofi?

Summary

How does Zoetis compare to GSK?

Summary

How does Zoetis compare to Takeda Pharmaceutical?

Summary

How does Zoetis compare to Teva Pharmaceutical Industries?

Summary

How does Zoetis compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zoetis (ZTS) Competitors

ZTS vs. SNY, GSK, TAK, TEVA, and ONC

How does Zoetis compare to Sanofi?

Do insiders & institutionals have more ownership in ZTS or SNY?

Which has higher valuation & earnings, ZTS or SNY?

Does the media favor ZTS or SNY?

Is ZTS or SNY a better dividend stock?

Which has more volatility and risk, ZTS or SNY?

Do analysts recommend ZTS or SNY?

Is ZTS or SNY more profitable?

Summary

How does Zoetis compare to GSK?

Which has better earnings & valuation, ZTS or GSK?

Which has more volatility and risk, ZTS or GSK?

Does the media refer more to ZTS or GSK?

Do analysts recommend ZTS or GSK?

Do institutionals and insiders believe in ZTS or GSK?

Is ZTS or GSK a better dividend stock?

Is ZTS or GSK more profitable?

Summary

How does Zoetis compare to Takeda Pharmaceutical?

Is TAK or ZTS more profitable?

Which has more volatility and risk, TAK or ZTS?

Do insiders & institutionals have more ownership in TAK or ZTS?

Does the media favor TAK or ZTS?

Which has stronger earnings and valuation, TAK or ZTS?

Do analysts prefer TAK or ZTS?

Is TAK or ZTS a better dividend stock?

Summary

How does Zoetis compare to Teva Pharmaceutical Industries?

Do institutionals & insiders hold more shares of TEVA or ZTS?

Is TEVA or ZTS more profitable?

Do analysts recommend TEVA or ZTS?

Which has more risk and volatility, TEVA or ZTS?

Which has preferable valuation and earnings, TEVA or ZTS?

Does the media favor TEVA or ZTS?

Summary

How does Zoetis compare to BeOne Medicines?

Is ONC or ZTS more profitable?

Do analysts recommend ONC or ZTS?

Does the media favor ONC or ZTS?

Do institutionals and insiders believe in ONC or ZTS?

Which has better earnings and valuation, ONC or ZTS?

Which has more risk & volatility, ONC or ZTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools